SAB Biotherapeutics, Inc.
SABSHealthcare|Biotechnology|US
$3.03
+0.09 (+3.06%)
DCF Value
$0.04
Tangible Book / Share
$2.26
Cash / Share
$1.12
About
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Stock Price
-2.3%(1Y)
1M
+4.8%
3M
-22.3%
6M
-26.3%
YTD
-19.0%
1Y
-5.3%
3Y
-68.6%
5Y
-96.4%
Pipeline Summary
9 total trials5
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
Completed: 5Unknown: 2Recruiting: 1Not Yet Recruiting: 1
Active Trials (1)
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
NCT07187531Type 1 Diabetes
Phase 2Recruiting
Enrollment: 159 participants
Key Facts
Market Cap$275.7M
Employees86 (+37% YoY)
CEOSamuel J. Reich
IPO DateFeb 9, 2021
Beta0.58
52-Week Range$2.44 – $5.15
Avg Volume532,454
ExchangeNASDAQ
Websitesab.bio
Ownership
Float89.6%
Shares Outstanding91.0M
Recent Insider Trades
Kropotova AlexandraTAX W/H
Sep 17, 2026473 shares
Kropotova AlexandraTAX W/H
Jun 25, 2026988 shares
Kropotova AlexandraTAX W/H
Mar 24, 2026988 shares
Sullivan Eddie JoeAWARD
Feb 3, 20263,000,000 shares @ $4.45
Reich Samuel JAWARD
Feb 3, 20264,800,000 shares @ $4.45
Peers
Recent News
What SAB Biotherapeutics (SABS) Said on Its Q3 Earnings Call
Nov 6, 2026 · marketbeat.com
SAB Biotherapeutics, Inc. (SABS) Q3 2026 Earnings Call Transcript
Nov 6, 2026 · seekingalpha.com
SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights
Nov 5, 2026 · globenewswire.com
SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
Oct 29, 2026 · globenewswire.com
SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform
Oct 23, 2026 · marketbeat.com
Data last updated: Nov 9, 2026, 04:32 AM